Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study

Grith Petersen Eng1,2,3*, Pierre Bouchelouche1, Else Marie Bartels3, Henning Bliddal3, Klaus Bendtzen4, Michael Stoltenberg2

1 Department of Clinical Biochemistry, Zealand University Hospital, Køge, Denmark, 2 Department of Rheumatology, Zealand University Hospital, Køge, Denmark, 3 The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, 4 Institute for Inflammation Research, Copenhagen University Hospital, Rigshospitalet, Denmark

* eng@dadlnet.dk

Abstract

Objectives

With the present study we wanted to explore the impact of treatment with a tumor necrosis factor-α-inhibitor (TNFi) on levels of soluble biomarkers in rheumatoid arthritis (RA) patients and to identify predictors of impaired drug levels and development of anti-TNFi antibodies (anti-TNFi Abs).

Methods

Blood samples from 26 patients with established RA were taken at baseline and following 6 months of treatment with adalimumab or infliximab. Samples were analyzed for levels of TNFi, interleukin (IL)-6, and soluble TNF-receptors 1 and -2 (sTNF-R1 and -2) and for presence of anti-TNFi Abs. Clinical and demographic data were recorded as well.

Results

During the initial 6 months treatment, DAS28(CRP) (Disease activity score in 28 joints using C-reactive protein) and levels of IL-6 and sTNF-R2 decreased significantly in patients without anti-TNFi Abs and in patients retaining detectable drug levels. The levels of other tested cytokines (TNF-α, TNF-β, IL-1ra, IL-1b, IL-8, IL-10, IL-12(p70), IL-13, IL-17A, IL-17F, and IL-33) were generally below detection limits. Higher baseline levels of IL-6 associated with undetectable levels of TNFi at follow-up. Anti-TNFi Abs were associated with decreased drug levels, but no predictors for anti-TNFi Ab development could be found.
**Conclusion**

The effect of treatment with TNFi on RA disease activity depends on levels of active drug, and by presence of anti-TNFi Abs. In patients who retain detectable drug levels, and in the absence of anti-TNFi Abs, clinical outcome is improved during treatment, and circulating levels of IL-6 and sTNF-R2 decrease. Baseline levels of IL-6 may predict depletion of TNFi and may identify patients at risk of treatment failure.

**Introduction**

Although biological TNF-α inhibitors (TNFi) have revolutionized the treatment of rheumatoid arthritis (RA) and other autoimmune inflammatory diseases, only one third of RA patients will experience a sustained treatment response \[1–3\]. Higher serum concentrations of TNFi are associated with better clinical outcome, whereas anti-TNFi antibodies (Abs) are associated with infusion reactions and treatment failure. As yet, efforts to identify other predictors of treatment response have had little success \[4–8\], although higher baseline levels of IL-6 may predict efficacy of infliximab treatment \[9\].

Anti-TNFi Abs may develop in patients treated with a TNFi, and their presence in the patient is associated with lower levels of bioactive TNFi, impaired clinical efficacy, and adverse reactions \[6;10–14\]. Anti-TNFi Abs are more often detected in patients treated with adalimumab (Humira®) and infliximab (Remicade®) than in patients treated with other available TNFi \[13\]. It is, however, still unknown why some patients develop anti-TNFi Abs, while others do not. Patients developing anti-TNFi Abs most often do so within the first 6–12 months of treatment, but measurable anti-TNFi Abs may also develop after several years of treatment \[11\].

While TNFi selectively target TNF-α and, in case of etanercept, TNF-β as well, the secondary effects on the various components of the immune system are only vaguely understood \[15\]. However, interleukin (IL)-6, another pro-inflammatory cytokine, also appears to be a key cytokine in the inflammatory cascade fuelling inflammation in RA \[16\]. Thus, IL-6 is elevated in serum and synovia of patients with active RA, and decreases in responders to TNFi therapy \[15;17;18\].

The soluble TNF-α receptors 1 and 2 (sTNF-R1 and sTNF-R2) are extracellular products of enzymatic cleavage of membrane-bound TNF-R1 and TNF-R2. These naturally occurring extracellular TNF-receptors are known to down-regulate TNF-α activity, thus counteracting inflammatory responses initiated by TNF-α. Both sTNF-R1 and -R2 are elevated in patients with RA, and sTNF-R2 is known to correlate with disease activity in RA and in other inflammatory diseases \[19;20\].

To identify easily obtainable biomarkers, which might predict the development and therapeoutic consequences of anti-TNFi Ab, we investigated early appearance of circulating anti-TNFi Ab and corresponding levels of TNFi in RA patients, and related the anti-TNFi Ab and drug levels to serum levels of IL-6, sTNF-R1 and sTNF-R2.

**Patients and Methods**

**Study design and population**

The study was conducted in accordance with the Helsinki Declaration (www.wma.net/en/30publications/10policies/b3/) and approved by the local ethics committee (KF 01-045/03),...
and written informed consent was obtained from all patients prior to inclusion. The patients participating in this study were recruited from a cohort with established RA according to the American College of Rheumatology (ACR) 1987 criteria [21]. All started treatment with a biological TNFi during the period 2003–2007 at the outpatient clinic at the University Hospital of Copenhagen, Frederiksberg, Denmark, as earlier described in detail [22]. Patients were monitored at baseline and at follow-up, including clinical examination, blood sampling for experimental and para-clinical measures, disease activity score in 28 joints and with the use of C-reactive protein (DAS28(CRP)), and imaging in the form of ultrasound and magnetic resonance imaging (MRI). In this cohort, the choice of TNF-α inhibitor was at the treating physician’s discretion. The patients included in the study received standard dose and treatment interval of TNFi (Adalimumab 40 mg s.c. /2 weeks, Infliximab induction regimen of 3 mg/kg at weeks 0, 2, 6 and then 3 mg/kg every 8 weeks. In the present study, patients treated with adalimumab or infliximab who sustained therapy for at least 6 months were selected. Only patients with adequate baseline and 6-month follow-up blood samples were included. All experimental laboratory analyses were carried out in a blinded manner.

**Laboratory analysis**

Baseline and follow-up blood samples were taken in the morning, immediately before administration of TNFi. All patients were fasting at sampling. Without delay, serum was produced and stored at -80°C until assayed. Blood samples at scheduled 6-months follow-up also were taken on the day of the treatment, immediately before the planned administration of TNFi.

Immunoglobulin M rheumatoid factor (IgM-RF) was measured at Department of Clinical Biochemistry at Slagelse Hospital, Denmark, using immuno-turbidimetric analysis on Cobas 6000 c-501 (F. Hoffmann-La Roche Ltd., Hvidovre, Denmark). IgM-RF was considered positive at values above 14 IU/ml.

CRP was measured at the Department of Clinical Biochemistry, Copenhagen University Hospital, Frederiksberg, using immunometric analysis on Vitros 5.1FS (Ortho Clinical Diagnostics Inc., Raritan NJ, USA).

**Concentrations of TNFi and anti-TNFi antibodies.** The levels of bioactive adalimumab and infliximab were measured using reporter gene assays (RGAs) iLite™ Infliximab Bioassay and iLite™ Adalimumab Bioassay, respectively (Biomonitor, Copenhagen, Denmark), as previously described [23]. Detection limit was 0.7 μg/ml for both assays, and results below detection were set to the detection limit.

Anti-adalimumab and anti-infliximab antibodies were detected in serum using fluid-phase radioimmunoassay (RIA) (Biomonitor), as previously detailed [4]. Anti-TNFi Ab-positivity was defined as detectable levels (i.e., above the limit of quantification of 10 arbitrary units/ml of both anti-adalimumab and anti-infliximab antibodies).

**Concentrations of IL-6, sTNF-R1 and sTNF-R2.** IL-6, sTNF-R1, and sTNF-R2 were measured in serum using commercially available assays according to the manufacturers’ directions. The analyses were performed at the Institute for Inflammation Research, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

IL-6 was measured using a Bio-Plex Pro™ Human Th17 Cytokine Assay (Bio-Rad Laboratories, Hercules, CA, USA) as part of a kit measuring a range of cytokines including IL-1β, IL-10, IL-17A, IL-17F, IL-33 and TNF-α. Test results were read using the Luminex 100 System (Luminex, Austin, TX, USA). The sensitivity of the assay for IL-6 was 2 pg/ml. Levels of IL-6 below the detection limit were set to the median value of 1 pg/ml. The sensitivity of the assay for the remainder of cytokines was 0.2 pg/ml for IL-1β, 11 pg/ml for IL-10, 3 pg/ml for IL-17A, 9 pg/ml for IL-17F, 5 pg/ml for IL-33, and 1 pg/ml for TNF-α. The samples also were tested for...
levels of IL-1ra, IL-8, IL-12(p70), IL-13 and TNF-β using Bio-Plex Pro™ Human Cytokine Assay (Bio-Rad Laboratories). The sensitivity of this assay was 64 pg/ml for IL-1ra, 7 pg/ml for IL-8, 9 pg/ml for IL-12(p70), 10 pg/ml for IL-13 and 6 pg/ml for TNF-β.

sTNF-R1 and sTNF-R2 were measured using Quantikine immunoassays DRT100 and DRT200 (R&D Systems, Minneapolis, MN, USA). These assays are solid-phase enzyme linked immuno sorbent assays (ELISAs), and the sensitivities of the assays were 40 pg/ml and 16 pg/ml, respectively. The upper detection limit was 3750 pg/ml, and levels of sTNFR-R2 above detection were set to this upper detection limit.

Statistics

Median and interquartile range (IQR) are reported for continuous variables, whereas frequency and percentage (%) and 95% confidence intervals (CI) are reported for categorical variables.

For the comparison of continuous data, the nonparametric Mann-Whitney test was used. For the comparison of paired data, the Wilcoxon matched pairs test was performed. For analysis of categorical data, the Fisher’s exact test was applied.

Two-sided p-values less than 0.05 were considered significant. Statistical analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA) and GraphPad Prism version 5.04 (GraphPad Software, San Diego, CA, USA).

Results

A total of 26 patients with RA were included from the cohort (for the selection process, see Fig 1). Fifteen patients were treated with adalimumab, and 11 patients were treated with infliximab (for baseline characteristics, see Table 1). None of the participants were exposed to steroid treatment during the study, and only a few patients received sulfasalazine. The patients treated with adalimumab or infliximab did not differ in any of the baseline characteristics, neither did
they differ in baseline levels of measured biomarkers. During the first 6 months of treatment with adalimumab or infliximab, DAS28(CRP) declined from 4.9 (4.2–5.7) to 3.5 (2.6–4.4) \((p < 0.001)\) in the entire group, whereas the median level of CRP did not change significantly, from 5.0 (1.8–36) mg/ml to 3.3 (1.4–9) mg/ml, respectively \((p = 0.0535)\). There was no difference in effect on DAS28(CRP), CRP, IL-6 or sTNF-R1 and -R2 between patients treated with adalimumab or infliximab. Both levels of IL-6 and sTNF-R2 decreased significantly during treatment \((\text{Fig 2})\). IL-6 decreased from 8 (1–36) pg/ml at baseline to 1 (1–5) pg/ml after 6 months treatment \((p = 0.009)\). sTNF-R2 decreased from 3092 (2642–3750) pg/ml at baseline to 2604 (2361–3079) pg/ml at follow-up \((p = 0.0071)\). Levels of sTNF-R1 did not change significantly during treatment from 1152 (976–1380) pg/ml to 1135 (919–1281) pg/ml \((p = 0.2818)\). The levels of the other tested cytokines (TNF-\(\alpha\), IL-1b, IL-10, IL-17A, IL-17F, IL-33, TNF-\(\beta\), IL-1ra, IL-8, IL-12(p70) and IL-13) were generally below detection limits of the kits (data not shown).

### Levels of TNFi and development of anti-TNFi antibodies

Undetectable levels of TNFi were present in two patients treated with adalimumab (13% (2–39%)) and in four patients treated with infliximab (36% (14–64%). In patients with detectable levels of TNFi at follow-up, DAS28(CRP) and the level of IL-6 and sTNF-R2 decreased significantly during treatment, while this was not the case in the patients with undetectable TNFi (Table 2). Regarding the predictive value of baseline biomarkers, patients with undetectable levels of TNFi at follow-up had higher baseline levels of IL-6 (Table 2). The groups of patients with detectable and undetectable levels of TNFi did not differ in terms of age, gender, use of methotrexate, or the number of tender or swollen joints at baseline (data not shown), baseline DAS28(CRP), or baseline CRP (Table 2).

During the first 6 months of treatment with either of the TNFi, 6 out of 26 patients (23% (11–42%)) developed anti-TNFi Abs. Among these 6 patients, 4 had levels of TNFi below the detection limit. In the group of 20 patients without anti-TNFi Abs, 2 had undetectable levels of TNFi at follow-up.

### Table 1. Baseline characteristics of the 26 rheumatoid arthritis patients included in the study.

| TNFi/Characteristic | Adalimumab (n = 15) | Infliximab (n = 11) | Total (n = 26) |
|---------------------|---------------------|---------------------|---------------|
| Male gender, n (%)  | 4 (27)              | 4 (36)              | 8 (31)        |
| Age, years          | 53 (39–64)          | 54 (49–61)          | 54 (41–61)    |
| IgM-RF positive, n (%) | 11 (73)     | 8 (73)              | 19 (73)       |
| Previous biological DMARD, n (%) | 5 (33) | 2 (18)              | 7 (27)        |
| Concomitant MTX, n (%) | 7 (47)    | 8 (72)              | 15 (58)       |
| MTX, mg/week        | 17.5 (10–20)        | 17.5 (11.25–23.75)  | 17.5 (10–20)  |
| Disease duration, years | 5 (2–16) | 6 (2–10)           | 6 (2–12)      |
| DAS28(CRP)           | 5.0 (4.2–5.4)       | 5.3 (4.4–6.0)       | 5.0 (4.3–5.8) |
| No. of tender joints | 8 (5–16)           | 8 (4–17)            | 8 (5–16)      |
| No. of swollen joints | 6 (2–8)     | 4 (2–7)             | 5 (2–8)       |
| CRP, mg/ml           | 6.0 (2.0–34.0)      | 4.0 (1.0–36.0)      | 5.0 (1.8–36.0) |
| IL-6 pg/ml           | 8 (1–26)           | 7 (1–40)            | 8 (1–36)      |
| sTNF-R1 pg/ml        | 1105 (946–1340)     | 1201 (1006–1481)    | 1152 (976–1380) |
| sTNF-R2 pg/ml        | 3100 (2777–3750)    | 2981 (2143–3750)    | 3092 (2642–3750) |

* except when otherwise indicated, values are median (IQR); IgM-RF = IgM rheumatoid factor; DMARD = Disease-modifying antirheumatic drug; DAS28 (CRP) = Disease activity score in 28 joints based on C-reactive protein (CRP); MTX = methotrexate.

doi:10.1371/journal.pone.0162316.t001
The development of anti-TNFi Abs was evenly distributed, with 3 out of 15 patients in the group treated with adalimumab (20% (6–46%)) and 3 out of 11 patients in the group treated with infliximab (27% (9–57%). The concentration of TNFi for each of the drugs corresponded with anti-TNFi Ab status, as presence of anti-TNFi Abs was associated with decreased levels of adalimumab or infliximab (Fig 3).

In patients treated with adalimumab, median drug level was 2.6 (0.7–5.8) μg/ml in the patients with anti-TNFi Abs and 9.8 (6.3–14.9) μg/ml in patients without anti-TNFi Abs (p = 0.043). In patients treated with infliximab, all patients with anti-TNFi Abs had a drug level below detection limit of 0.7 μg/ml, while median level of drug was 3.3 (1.0–5.8) μg/ml in patients without anti-TNFi Abs (p = 0.037).

Absence of anti-TNFi Abs after 6 months of therapy was associated with a decline in DAS28 (CRP) and a decline in levels of IL-6 and sTNF-R2, while levels of sTNF-R1 remained unchanged (Table 3). There was no significant drop in clinical disease activity score or in levels of IL-6 and soluble TNF receptors in patients with anti-TNFi Abs, and this group showed higher levels of sTNF-R2 at follow-up compared with patients without anti-TNFi Abs. Production of anti-

![Fig 2. Changes in levels of IL-6, sTNF-R1 and sTNF-R2 following 6 months of treatment with adalimumab or infliximab.](image)
TNFi Abs was not associated with age, gender, level of IgM-RF, concomitant methotrexate, disease duration, or the number of tender or swollen joints (data not shown). Nor was it associated with the baseline level of DAS28(CRP), CRP, IL-6, sTNF-R1 or sTNF-R2 (Table 3).

Table 2. Clinical variables and biomarkers according to whether TNFi was detectable in the patients’ blood following 6 months of treatment with adalimumab or infliximab.

|                                | Test (n = 20)                            | Test (n = 6)                            | p       |
|--------------------------------|------------------------------------------|-----------------------------------------|---------|
|                                | Concomitant MTX, n (%                    | Concomitant MTX, n (%)                  | 0.197   |
| MTX, mg/week                   | 10 (50)                                  | 5 (83)                                  |         |
| DAS28(CRP)Baseline             | n = 18                                   | n = 6                                   |         |
| Follow-up *                   | 4.8 (3.9–5.7)                            | 5.1 (4.7–6.1)                           | 0.408   |
|                                | *3.4 (2.6–4.4)                           | *4.2 (3.0–5.2)                          | 0.183   |
|                                | <0.001                                   | *0.156                                  |         |
| CRP, mg/mlBaseline            | n = 19                                   | n = 6                                   |         |
| Follow-up *                   | 2 (1–13)                                 | 36 (10–43)                              | 0.089   |
|                                | *2 (1–7)                                 | *17 (5–31)                              | 0.014   |
|                                | *0.1243                                  | *0.5625                                 |         |
| IL-6, pg/mlBaseline           | n = 6                                    | n = 6                                   |         |
| Follow-up *                   | 6 (1–22)                                 | 36 (10–43)                              | 0.031   |
|                                | *1 (1–3)                                 | *11 (1–38)                              | 0.180   |
|                                | *0.0143                                  | *0.3125                                 |         |
| sTNF-R1, pg/mlBaseline        | n = 1152                                 | n = 1197                                |         |
| Follow-up *                   | 1103 (861–1268)                          | 1197 (959–1369)                         | 0.738   |
|                                | *0.061                                   | *1248 (1133–1650)                       | 0.073   |
|                                |                                         |                                         |         |
| sTNF-R2, pg/mlBaseline        | n = 3033                                 | n = 3750                                |         |
| Follow-up *                   | 2563 (2210–2892)                         | 2907 (2589–3265)                        | 0.165   |
|                                | *0.011                                   | *0.3125                                 | 0.152   |

*except when otherwise indicated, values are median (IQR); IgM-RF = IgM rheumatoid factor; MTX = methotrexate; DAS28(CRP) = Disease activity score in 28 joints based on C-reactive protein (CRP). doi:10.1371/journal.pone.0162316.t002

Fig 3. Serum TNFi levels in relation to antibodies against adalimumab and infliximab following six months of treatment. Antibodies towards the prescribed TNFi (anti-TNFi Abs) were measured in 26 patients with rheumatoid arthritis, using radioimmunoassay. Patients were treated with either adalimumab (A) or infliximab (B). Functional levels of TNFi were determined using reporter gene assays. Presence of anti-TNFi Abs correlated with lower levels of TNFi for both drugs (p < 0.05). Medians and interquartile ranges are shown. doi:10.1371/journal.pone.0162316.g003
Early development of anti-TNFi Abs in a cohort of RA patients and the impact of treatment on readily available soluble biomarkers were investigated in this study. As expected, treatment with TNFi had an overall impact on disease activity by lowering DAS28(CRP). To our surprise, however, we did not find a general decrease in the levels of CRP during treatment, and we ascribe this to our low baseline CRP. In contrast, TNFi therapy resulted in reduced circulating levels of IL-6, which is likely to reflect the drug-induced decrease in inflammatory activity in accordance with previous findings [24;25].

To our knowledge, the association of TNFi therapy with lowered circulating levels of sTNF-R2 has not previously been demonstrated, although others have tried [15;26]. Genome sequencing have found that mutations in TNF-R2 are associated with decreased response to TNFi treatment [27], which suggests that clinical effect of TNFi could be mediated, at least in part, by TNF-R2. In vitro, infliximab increases the release of TNF-R2 from human monocytes and reduces the expression of the receptor [28]. These actions increase the TNF-α neutralizing activity and lower the cellular response to TNF-α. The receptor shedding and the decreased expression may explain the decrease in circulating sTNF-R2 seen following infliximab treatment, but also the observed cytotoxic effect of infliximab and adalimumab on TNF-α expressing cells may contribute to the lowered levels of sTNF-R2 [29;30].

The frequency of anti-TNFi Ab-positivity was 23%, corresponding to previous findings ranging from 19–44% [4;11;12]. Although not statistically significant, the observed difference in immunogenicity between adalimumab (20% anti-TNFi Ab-positive) and infliximab (27% anti-TNFi Ab-positive) are in accordance with previous observations, in which infliximab appears slightly more immunogenic than adalimumab [4;6;11;12;31–35]. Previous studies have

| Table 3. Variables according to development of anti-TNFi Ab production following 6 months of treatment with adalimumab or infliximab. |
| --- |
| • Concomitant MTX, n (%) | Anti-TNFi Ab neg. (n = 20) | Anti-TNFi Ab pos. (n = 6) | p |
| • MTX, mg/week | 16.25 (11.25–20) | 17.5 10–25.9 | 0.884 |
| • DAS28(CRP)Baseline | n = 18 | n = 5 | 0.125 |
| • Follow-up | 4.9 (4.0–5.7) | 5.7 (4.4–6.6) | 0.812 |
| • p | 3.4 (2.6–4.4) | 4.0 (2.4–4.7) | 0.152 |
| • CRP, mg/ml | n = 18 | n = 6 | 0.674 |
| • Baseline | 4 (1–25) | 20 (3–43) | 0.103 |
| • Follow-up | 3 (1–9) | 9 (3–31) | 0.339 |
| • p | <0.001 | 0.0729 | 0.040 |
| • IL-6, pg/ml | n = 18 | n = 6 | 0.323 |
| • Baseline | 7 (1–25) | 33 (1–111) | 0.602 |
| • Follow-up | 1 (1–7) | 1 (1–22) | 0.316 |
| • p | 0.020 | 0.079 |
| • sTNF-R1, pg/ml | n = 18 | n = 6 | 0.879 |
| • Baseline | 1200 (956–1369) | 1104 (978–1998) | 0.738 |
| • Follow-up | 1135 (926–1277) | 1160 (842–1650) | 0.688 |
| • p | 0.220 | 0.879 |
| • sTNF-R2, pg/ml | n = 18 | n = 6 | 0.829 |
| • Baseline | 3092 (2525–3750) | 3213 (2639–3750) | 0.067 |
| • Follow-up | 2583 (2210–2850) | 3087 (2671–3581) | 0.813 |
| • p | 0.005 | 0.813 |

*except when otherwise indicated, values are median (IQR); IgM- RF = IgM rheumatoid factor; MTX = methotrexate; DAS28(CRP) = Disease activity score in 28 joints based on C-reactive protein (CRP).

doi:10.1371/journal.pone.0162316.t003

Discussion

Early development of anti-TNFi Abs in a cohort of RA patients and the impact of treatment on readily available soluble biomarkers were investigated in this study. As expected, treatment with TNFi had an overall impact on disease activity by lowering DAS28(CRP). To our surprise, however, we did not find a general decrease in the levels of CRP during treatment, and we ascribe this to our low baseline CRP. In contrast, TNFi therapy resulted in reduced circulating levels of IL-6, which is likely to reflect the drug-induced decrease in inflammatory activity in accordance with previous findings [24;25].

To our knowledge, the association of TNFi therapy with lowered circulating levels of sTNF-R2 has not previously been demonstrated, although others have tried [15;26]. Genome sequencing have found that mutations in TNF-R2 are associated with decreased response to TNFi treatment [27], which suggests that clinical effect of TNFi could be mediated, at least in part, by TNF-R2. In vitro, infliximab increases the release of TNF-R2 from human monocytes and reduces the expression of the receptor [28]. These actions increase the TNF-α neutralizing activity and lower the cellular response to TNF-α. The receptor shedding and the decreased expression may explain the decrease in circulating sTNF-R2 seen following infliximab treatment, but also the observed cytotoxic effect of infliximab and adalimumab on TNF-α expressing cells may contribute to the lowered levels of sTNF-R2 [29;30].

The frequency of anti-TNFi Ab-positivity was 23%, corresponding to previous findings ranging from 19–44% [4;11;12]. Although not statistically significant, the observed difference in immunogenicity between adalimumab (20% anti-TNFi Ab-positive) and infliximab (27% anti-TNFi Ab-positive) are in accordance with previous observations, in which infliximab appears slightly more immunogenic than adalimumab [4;6;11;12;31–35]. Previous studies have
shown that patients with high baseline disease activity [11] or lower levels of TNFi early in the treatment course [4] have increased risk of developing anti-TNF Abs. We were not able to corroborate such an association and found no associations between baseline characteristics or biomarkers and presence of anti-TNF Abs. However, as previously shown, the presence of anti-TNF Abs correlated with simultaneous low or undetectable drug levels and with an inability to decrease clinical disease activity [4;6;11;12;34]. These impaired drug levels were preceded by higher baseline levels of IL-6 and a trend towards higher baseline CRP.

A few remarks on the strengths and limitations of this study must be made. Sera were always sampled when drug levels were at their lowest (trough) in a treatment cycle, and sera used for biomarker analysis were meticulously prepared in order to preserve the biomarkers in the best way possible. Centrifugation was initiated instantly following sedimentation, sera were frozen immediately after preparation, and samples used for the analyses were not previously thawed. As most of the out-of-range values for sTNF-R2 were from baseline samples, the inability to determine precise concentrations of high levels of the receptor may have underestimated the impact of TNFi on this biomarker. Although the higher baseline levels of CRP in patients who later had impaired drug levels did not significantly differ from the rest, a \( p \)-value of 0.089 in this exploratory study calls for attention as the finding may reflect a type 2 error due to a limited study population. As previously explained, development of anti-TNF Abs occur most rapidly during the first 6–12 months of therapy. We may have underestimated the immunogenicity of the two TNFi in this study by choosing the 6-month follow-up. Pragmatically, this was our best option, as widening the time frame to 12 months would have limited our sample size considerably.

Conclusion

Our findings underline that anti-TNF Abs have an impact on levels of TNFi and we further emphasize the impact TNFi levels have on modulating inflammatory activity and ensuring clinical efficacy. Finding that increased baseline levels of IL-6 are associated with undetectable levels of TNFi after 6 months of therapy suggest that in patients with a higher inflammatory load at baseline, treatment should be intensified early on, to ensure adequate disease control. Attention to baseline inflammatory activity may foresee later treatment failure by inadequate drug levels and may promote individualized treatment regimens, improving the clinical outcome for the patient. The results from this small-scale study should be confirmed in larger cohorts.

Supporting Information

S1 Table. (XLSX)

Acknowledgments

This work was supported by Region Zealand and the Danish Rheumatism Association. These funds had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Author Contributions

Conceptualization: GE PB EB HB KB MS.

Data curation: GE EB.
Formal analysis: GE KB.
Funding acquisition: PB HB KB.
Investigation: GE EB HB KB.
Methodology: GE PB EB KB KB MS.
Project administration: GE.
Resources: GE PB EB HB KB.
Supervision: GE PB EB HB KB MS.
Validation: GE EB.
Visualization: GE PB EB KB MS.
Writing – original draft: GE.
Writing – review & editing: GE PB EB HB KB MS.

References

1. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000 Nov 30; 343(22):1594–602. PMID: 11096166

2. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999 Jan 28; 340(4):253–9. PMID: 9920948

3. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003 Jan; 48(1):35–45. PMID: 12528101

4. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006 Dec; 54(12):3782–9. PMID: 17133559

5. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007 Jul; 66(7):921–6. PMID: 17301106

6. Radstake TR, Svenson M, Eijssouts AM, van den Hoogen FH, Enevold C, van Riel PL, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009 Nov; 68(11):1739–45. doi: 10.1136/ard.2008.092833 PMID: 19019895

7. Pouw MF, Krieckaert CL, Nurmohamed MT, van der Kleij D, Aarden L, Rispens T, et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis 2013 Dec 10.

8. van den Broek M, Visser K, Allaart CF, Huizinga TW. Personalized medicine: predicting responses to therapy in patients with RA. Curr Opin Pharmacol 2013 Jun; 13(3):463–9. doi: 10.1016/j.coph.2013.03.006 PMID: 23578763

9. Hayashi S, Suzuki K, Yoshimoto K, Takeshita M, Kurasawa T, Yamaoka K, et al. Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate. Rheumatol Ther 2016; 3:155–66.

10. Bendtzen K. Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies? Arthritis Rheum 2011 Apr; 63(4):867–70. doi: 10.1002/art.30207 PMID: 21452309

11. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011 Apr 13; 305(14):1460–8. doi: 10.1001/jama.2011.406 PMID: 21486979
12. Pascual-Saliceto D, Plascencia C, Ramiro S, Nuno L, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 2011 Aug; 50(8):1445–52.

13. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Anti-drug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013 Feb; 72(2):165–78. doi: 10.1136/annrheumdis-2012-202545 PMID: 23178294

14. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013 Dec; 72(12):1947–55. doi: 10.1136/annrheumdis-2012-202220 PMID: 23223420

15. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999 Aug 1; 163(3):1521–8. PMID: 10415055

16. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2012 Jul; 51 Suppl 5:v3–11.

17. Hueber W, Tomooka BH, Battiwalla F, Li W, Monach PA, Tibshirani RJ, et al. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Res Ther 2009; 11(3):R76. doi: 10.1186/ar2706 PMID: 19460157

18. Kokkonen H, Soderstrom I, Rocklov J, Hallmans G, Lejon K, Rantapaa DS. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 2010 Feb; 62(2):383–91. doi: 10.1002/art.27186 PMID: 20112361

19. Valle Y, Ledezma-Lozano Y, Torres-Carrillo N, Padilla-Gutierrez JR, Navarro-Hernandez RE, Vazquez-Del MM, et al. Circulating TNFRI and TNFRII levels correlated with the disease activity score (DAS28) in rheumatoid arthritis. Scand J Rheumatol 2009; 38(5):332–5. doi: 10.1080/03009740902865456 PMID: 19579138

20. Spoettl T, Hausmann M, Kleibl F, Dirmieier A, Klump B, Hoffmann J, et al. Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. Inflamm Bowel Dis 2007 Jun; 13(6):727–32. PMID: 17260368

21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988 Mar; 31(3):315–24. PMID: 3587996

22. Ellegaard K, Christensen R, Torp-Pedersen S, Terslev L, Holm CC, Konig MJ, et al. Ultrasound Doppler measurements predict success of treatment with anti-TNF-α drug; in patients with rheumatoid arthritis: a prospective cohort study. Rheumatology (Oxford) 2011 Mar; 50(3):506–12.

23. Lallemand C, Kavrochorianou N, Steenholdt C, Bendtzen K, Ainsworth MA, Meritet JF, et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists. J Immunol Methods 2011 Oct 28; 373(1–2):229–39. doi: 10.1016/j.jim.2011.08.022 PMID: 21910993

24. Gottenberg JE, Dayer JM, Lukas C, Ducot B, Chiocchia G, Cantagrel A, et al. Serum IL-6 and IL-21 are up-regulated in chronic inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2012 Jul; 72(7):1640–5. doi: 10.1136/annrheumdis-2012-200975 PMID: 22532637

25. Maini RN, Feldmann M. How does infliximab work in rheumatoid arthritis? Arthritis Res Ther 2009; 11(3):R76. doi: 10.1186/ar2706 PMID: 19460157

26. Schulz M, Dotzlau H, Neeck G. Ankylosing spondylitis and rheumatoid arthritis: serum levels of TNF-II gene 676T polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis? Rheumatol Int 2008 Jul; 28(9):901–6. doi: 10.1007/s00296-008-0552-5 PMID: 18309487

27. Ongaro A, De MM, Pellati A, Caruso A, Ferretti S, Masieri FF, et al. Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNF-alpha therapy in rheumatoid arthritis? Rheumatol Int 2008 Jun; 28(6):981–6. doi: 10.1007/s00296-008-0552-5 PMID: 18309487

28. Ebert EC. Infliximab and the TNF-alpha system. Am J Physiol Gastrointest Liver Physiol 2009 Mar; 296(3):G612–G620. doi: 10.1152/ajpgi.90576.2008 PMID: 19136378

29. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995 Apr; 7(3):251–9. PMID: 7640345

30. Mitoma H, Horiiuchi T, Tsukamoto H, Tanimoto Y, Kimoto Y, Uchino A, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008 May; 58(5):1248–57. doi: 10.1002/art.23447 PMID: 18438640
31. Ducourau E, Mulleman D, Paintaud G, Miow Lin DC, Lauferon F, Ternant D, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011; 13(3):R105. doi: 10.1186/ar3386 PMID: 21708018

32. Kreckaert CL, Jamnitski A, Nurmohamed MT, Kostense PJ, Boers M, Wolbink G. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum 2012 Dec; 64(12):3850–5. doi: 10.1002/art.34680 PMID: 22933315

33. Krintel SB, Grunert VP, Hetland ML, Johansen JS, Rothfuss M, Palermo G, et al. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. Rheumatology (Oxford) 2013 Mar 4.

34. Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFalpha biologics in rheumatic diseases. Clin Rheumatol 2013 Oct; 32(10):1429–35. doi: 10.1007/s10067-013-2336-x PMID: 23887439

35. van der Maas A, van den Bemt BJ, Wolbink G, van den Hoogen FH, van Riel PL, den Broeder AA. Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. BMC Musculoskelet Disord 2012; 13:184. doi: 10.1186/1471-2474-13-184 PMID: 23006627